|Epigenomics AG -- USA Stock|| |
USD 4.98 0.55 12.42%
Member of the Supervisory Board
Prof. Dr. Guenther Reiter is Vice Chairman of the Supervisory Board at Epigenomics AG since November 5, 2014. He was Member of the Supervisory Board since June 28, 2005. He held several managing positions such as Manager Business Administration and Controlling at Trumpf GmbH Co. in Ditzingen and at last as Executive Member of the Hofkammer of Wuerttemberg. As a Dean and Prodean, Prof. Reiter was actively involved in the development of the European School of Business in Reutlingen as Professor. Furthermore, Prof. Dr. Reiter is Member of the Supervisory Board Deltoton GmbH. He graduated from Universitaet Tuebingen in Mathematics and in Business Economics.
Age: 62 Executive Since 2014
49 30 243 450 http://www.epigenomics.com
The company has return on total asset (ROA)
of (44.29) %
which means that it has lost $44.29 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (122.69) %
meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 607.04 K in total debt with debt to equity ratio (D/E) of 5.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Epigenomics AG has Current Ratio of 1.92 which is within standard range for the sector.
Epigenomics AG, a molecular diagnostics company, focuses on developing and commercializing in vitro diagnostic tests for the screening, early detection, and diagnosis of cancer in Germany and internationally. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany. Epigenomics AG is traded on OTC Market in USA.Epigenomics AG (EPGNF) is traded on OTC Market in USA. It is located in Geneststrasse 5 and employs 43 people.